早期妊娠母体pGCD59水平在预测新生儿低血糖中的作用——DALI研究子分析
该观察性研究纳入399例孕前BMI≥29的孕妇,在孕早期(<20周)行75g口服葡萄糖耐量试验时检测血浆糖化CD59(pGCD59),发现30例新生儿低血糖。pGCD59与新生儿低血糖患病率呈正相关;最高三分位组较低三分位组的新生儿低血糖比值比为2.41(95%CI 1.03-5.63),校正母体BMI后为2.28(95%CI 0.96-5.43)。作者认为pGCD59本身仅是一个一般的预测指标。
要点
- 孕早期母体pGCD59水平与新生儿低血糖患病率呈正相关(单因素方差分析P<.001)。
- pGCD59最高三分位组较低三分位组的新生儿低血糖OR为2.41(95%CI 1.03-5.63),校正母体BMI后OR为2.28(95%CI 0.96-5.43)。
- 交叉验证AUC为0.64(95%CI 0.54-0.74),校正母体BMI、年龄和种族后AUC为0.70(95%CI 0.56-0.78),作者认为该标志物本身仅是一般的预测指标。
核心结论
- 在BMI≥29的孕妇中,孕早期pGCD59水平与新生儿低血糖相关,但该标志物本身仅是一般的预测指标。
研究设计与样本
- 这是一项观察性研究,纳入孕前BMI≥29、筛查合格参加维生素D和生活方式干预妊娠期糖尿病(DALI)试验的孕妇,本分析包括399例妊娠。
- 在孕早期(<20周)行75g、2小时口服葡萄糖耐量试验时采集空腹母体样本,检测pGCD59水平。
- 研究结局新生儿低血糖定义为分娩后48小时内足跟采血毛细血管葡萄糖水平低于2.6 mmol/L。
主要发现
- 共识别30例新生儿低血糖。
- 孕早期母体pGCD59水平与新生儿低血糖患病率呈正相关(单因素方差分析,P<.001)。
- pGCD59最高三分位组孕妇所生新生儿较低三分位组的新生儿低血糖比值比为2.41(95%CI 1.03-5.63)。
- 校正母体BMI后,该比值比为2.28(95%CI 0.96-5.43)。
- 交叉验证AUC为0.64(95%CI 0.54-0.74);校正母体BMI、年龄和种族后,AUC为0.70(95%CI 0.56-0.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was to assess the association between early maternal levels of pGCD59 and NH. OBJECTIVE: The aim of this study was to assess the association between early pregnancy maternal levels of plasma glycated CD59 (pGCD59) and neonatal hypoglycemia (NH). METHODS: This is an observational study of pregnant women with a prepregnancy body mass index (BMI) greater than or equal to 29 screened for eligibility to participate in the Vitamin D and Lifestyle Intervention for Gestational Diabetes (DALI) trial. This analysis included 399 pregnancies. Levels of pGCD59 were measured in fasting maternal samples taken at the time of a 75-g, 2-hour oral glucose tolerance test performed in early pregnancy (< 20 weeks). NH, the study outcome, was defined as a heel-prick capillary glucose level of less than 2.6 mmol/L within 48 hours of delivery. RESULTS: We identified 30 infants with NH. Maternal levels of pGCD59 in early pregnancy were positively associated with the prevalence of NH (one-way analysis of variance, P < .001). The odds of NH were higher in infants from mothers in tertile 3 of pGCD59 levels compared to those from mothers in tertile 1 (odds ratio [OR]: 2.41; 95% CI, 1.03-5.63). However, this was attenuated when adjusted for maternal BMI (OR: 2.28; 95% CI, 0.96-5.43). The cross-validated area under the curve (AUC) was 0.64 (95% CI, 0.54-0.74), and adjusted for maternal BMI, age, and ethnicity, the AUC was 0.70 (95% CI, 0.56-0.78). CONCLUSION: Although pGCD59 levels in early pregnancy in women with BMI greater than or equal to 29 are associated with NH, our results indicate that this biomarker by itself is only a fair predictor of NH.
引用
- Bogdanet D, Luque-Fernandez MA, Toth-Castillo M, et al. The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia-Subanalysis of the DALI Study. J Clin Endocrinol Metab. 2022. PMID: 36054347. doi:10.1210/clinem/dgac498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。